title: Effects of testosterone treatment on body composition in males with testosterone deficiency syndrome.
abstract: OBJECTIVE
  We evaluated the safety of testosterone treatment and its efficacy on body composition in males with testosterone deficiency syndrome (TDS) over 24 months.
  
  
  METHODS
  50 males aged 50-65 years with TDS (Aging Males Symptoms Scale [AMS] > 26 and calculated free testosterone [cFT] 250 pmol/l) were administered 50 mg testosterone gel daily for one year. During the second year, patients received 1000 mg of testosterone undecanoate every 2-3 months. Outcome measures were clinical chemistry values and total testosterone; sex hormone-binding globulin and cFT, changes in AMS and International Prostate Symptom Score; and changes in body composition measured by dual-energy-x-ray absorptiometry.
  
  
  RESULTS
  There were no clinically significant changes in clinical chemistry safety parameters. There were significant improvements in both total and cFT and in AMS scores after three months (p < 0.001). Lean mass increased 2.35% at 12 months and 4.5% at 24 months, but proportionally more muscle mass was gained in arms and legs than in the trunk. Fat mass decreased 4.2% at 12 months and 9.1% at 24 months.
  
  
  CONCLUSIONS
  Testosterone treatment in males with TDS leads to body changes affecting lean and fat mass with significant improvement in AMS scores, and has an excellent safety profile.
authors.affiliation: Department of Urology, Hospital Universitari de Bellvitge , L`Hospitalet , Spain and.
authors.forename: Josep
authors.initials: J
authors.lastname: Rodriguez-Tolrà
authors.forename: Josep
authors.initials: J
authors.lastname: Torremadé Barreda
authors.forename: Luis
authors.initials: L
authors.lastname: del Rio
authors.forename: Silvana
authors.initials: S
authors.lastname: di Gregorio
authors.forename: Eladio
authors.initials: E
authors.lastname: Franco Miranda
mesh_terms: D015502:Absorptiometry, Photon / Q000379:methods; D000728:Androgens / Q000008:administration & dosage; D001823:Body Composition / Q000187:drug effects*; D004304:Dosage Forms; D005500:Follow-Up Studies; D020249:Hormone Replacement Therapy / Q000379:methods; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D013739:Testosterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood; D013995:Time; D016896:Treatment Outcome; D049629:Waist-Hip Ratio
chemical_list: D000728:Androgens; D004304:Dosage Forms; D012738:Sex Hormone-Binding Globulin; D013739:Testosterone; C010792:testosterone undecanoate